Mirabegron

Mirabegron

File:Mirabegron.svg
Clinical data
Trade names	Myrbetriq, Betanis, Betmiga, others
Other names	YM-178
AHFS/Drugs.com	Monograph
MedlinePlus	a612038
License data	US DailyMed: Mirabegron
Pregnancy category	AU: B3
Routes of administration	By mouth
ATC code	G04BD12 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	29–35%
Protein binding	71%
Metabolism	Liver via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase
Elimination half-life	50 hours
Excretion	Urine (55%), faeces (34%)
Identifiers
IUPAC name 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
CAS Number	223673-61-8
PubChem CID	9865528
DrugBank	DB08893
ChemSpider	8041219
UNII	MVR3JL3B2V
KEGG	D09535
ChEBI	CHEBI:65349
ChEMBL	ChEMBL2095212
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H24N4O2S
Molar mass	396.51 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(Nc1ccc(cc1)CCNC[C@H](O)c2ccccc2)Cc3nc(sc3)N
InChI InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1 Key:PBAPPPCECJKMCM-IBGZPJMESA-N

Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. It is taken by mouth.

Common side effects include high blood pressure, headaches, and urinary tract infections. Other significant side effects include urinary retention, irregular heart rate, and angioedema. It works by activating the β₃ adrenergic receptor in the bladder, resulting in its relaxation.

Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012. In 2023, it was the 214th most commonly prescribed medication in the United States, with more than 2 million prescriptions. It is available as a generic medication.

In the United Kingdom it is less preferred to antimuscarinic medication such as oxybutynin.

Medical uses

Mirabegron is used is in the treatment of overactive bladder. It works equally well to antimuscarinic medication such as solifenacin or tolterodine. In the United Kingdom it is less preferred to these agents.

Mirabegron is also indicated to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

Adverse effects

Adverse effects by incidence:

Very common (>10% incidence) adverse effects include:

• Elevated blood pressure

Common (1–10% incidence) adverse effects include:

• Dry mouth
• Nasopharyngitis
• Urinary tract infection (UTI)
• Headache
• Influenza
• Constipation
• Dizziness
• Joint pain
• Cystitis
• Back pain
• Upper respiratory tract infection (URTI)
• Sinusitis
• Diarrhea
• High heart rate
• Fatigue
• Abdominal pain
• Neoplasms (cancers)

Rare (<1% incidence) adverse effects include:

• Palpitations
• Blurred vision
• Glaucoma
• Indigestion
• Gastritis
• Abdominal distension
• Rhinitis
• Elevations in liver enzymes (GGTP, AST, ALT and LDH)
• Renal and urinary disorders (e.g., nephrolithiasis, bladder pain)
• Reproductive system disorders (e.g., vulvovaginal pruritus, vaginal infection)
• Skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema)
• Stevens–Johnson syndrome associated with increased serum ALT, AST and bilirubin
• Urinary retention

Research

As a selective beta-3 adrenergic agonist, mirabegron does not cause the cardiovascular adverse effects of other adrenergic agonists that are active at the beta-1 and beta-2 adrenergic receptors. Beta-3 adrenergic agonists activate brown adipose tissue (BAT) and increase energy expenditure, leading to research interest in their development as weight loss drugs. A combination of mirabegron and metformin was studied in mice and caused greater weight loss than either drug alone. A human study in obese individuals found an increase in insulin sensitivity but no significant weight change, which was hypothesized to be due to low levels of BAT in obese humans and/or the low dose of mirabegron used in the study.